This marks Huntsworth’s second acquisition under the ownership of Clayton, Dubilier & Rice and demonstrates the group’s commitment to strengthening its offerings in the healthcare category. Huntsworth, with the addition of Nucleus Global to the healthcare operating units of Huntsworth, MediStrava, the Evoke Group and The Creative Engagement Group– will provide pharmaceutical and biotechnology companies with the most complete suite of strategic counsel, medical affairs, market access, stakeholder engagement and marketing services across all therapeutic areas and across the entire drug development and commercialization lifecycle of molecule to medicine.
“The addition of Nucleus Global to Huntsworth creates one of the largest high science teams in the world to meet the increasingly complex needs of next generation prescription drug development,” said Paul Taaffe, CEO of Huntsworth. “Together, Nucleus Global, and Huntsworth are one of the most powerful combinations in healthcare communications.”
Nucleus was founded in 1986 and has become one of the largest medical specialist communications networks in the world. Globally, they have over 800 experts with 14 offices to help deliver world-class compliant events, publications and digital programmes for the major healthcare and medical brands around the world.
“We are excited to combine our expertise with the breadth of solutions across Huntsworth to deliver even more value to our clients, and our teams, which will help them capitalise on their opportunities to provide patients with the most effective healthcare solutions,” said Stephen Cameron, Chairman of Nucleus Global.
Nucleus Global’s Founder and Chair, Stephen Cameron will join the main Board of Huntsworth and continue to lead Nucleus Global.